Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097328 - FIXED DOSE PHARMACEUTICAL COMPOSITIONS FOR TREATING OVERACTIVE BLADDER AND RELATED CONDITIONS

Publication Number WO/2020/097328
Publication Date 14.05.2020
International Application No. PCT/US2019/060264
International Filing Date 07.11.2019
IPC
A61K 9/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61K 31/426 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 31/4725 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
CPC
A61K 31/426
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 31/4725
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
A61K 9/2009
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2009Inorganic compounds
A61K 9/2018
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2013Organic compounds, e.g. phospholipids, fats
2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
A61K 9/2031
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2022Organic macromolecular compounds
2031obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
A61K 9/2054
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2022Organic macromolecular compounds
205Polysaccharides, e.g. alginate, gums; Cyclodextrin
2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applicants
  • VELICEPT THERAPEUTICS, INC [US]/[US]
Inventors
  • STEVENS, JR., Raymond E.
  • BENNYHOFF, Dale
Agents
  • SRINIVAS, Harish
  • STAKLEFF, N. Nicole
Priority Data
62/756,83607.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FIXED DOSE PHARMACEUTICAL COMPOSITIONS FOR TREATING OVERACTIVE BLADDER AND RELATED CONDITIONS
(FR) COMPOSITIONS PHARMACEUTIQUES À DOSE FIXE POUR LE TRAITEMENT D'UNE VESSIE HYPERACTIVE ET D'ÉTATS ASSOCIÉS
Abstract
(EN)
The present invention relates to fixed dose pharmaceutical compositions for oral administration comprising a core of a therapeutically effective amount of mirabegron, or a pharmaceutically acceptable salt thereof, coated with a layer of a therapeutically effective amount of solifenacin, or a pharmaceutically acceptable salt thereof, and methods of use for treating overactive bladder and related conditions. The formulations described herein have desirable stability and pharmacokinetic characteristics.
(FR)
La présente invention concerne des compositions pharmaceutiques à dose fixe pour une administration orale comprenant un noyau d'une quantité thérapeutiquement efficace de mirabegron, ou d'un sel pharmaceutiquement acceptable de celui-ci, revêtu d'une couche d'une quantité thérapeutiquement efficace de solifénacine, ou d'un sel pharmaceutiquement acceptable de celle-ci, et des procédés d'utilisation pour traiter une vessie hyperactive et des états associés. Les formulations décrites dans les présentes ont des caractéristiques de stabilité et de pharmacocinétique souhaitables.
Latest bibliographic data on file with the International Bureau